Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Metacrine stock

Own Metacrine stock in just a few minutes.

Metacrine, Inc is a biotechnology business based in the US. Metacrine shares (MTCR) are listed on the NASDAQ and all prices are listed in US Dollars. Metacrine employs 35 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Metacrine

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Metacrine share price

Use our graph to track the performance of MTCR stocks over time.

Metacrine shares at a glance

Information last updated 2021-04-21.
52-week range$3.72 - $16.19
50-day moving average $6.83
200-day moving average $8.61
Wall St. target price$20.58
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Metacrine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Metacrine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Metacrine financials

Revenue TTM $2.2 million
Gross profit TTM $-26,790,000
Return on assets TTM -27.88%
Return on equity TTM -55.81%
Profit margin 0%
Book value N/A
Market capitalisation $114.2 million

TTM: trailing 12 months

Shorting Metacrine shares

There are currently 177,205 Metacrine shares held short by investors – that's known as Metacrine's "short interest". This figure is 13.2% up from 156,493 last month.

There are a few different ways that this level of interest in shorting Metacrine shares can be evaluated.

Metacrine's "short interest ratio" (SIR)

Metacrine's "short interest ratio" (SIR) is the quantity of Metacrine shares currently shorted divided by the average quantity of Metacrine shares traded daily (recently around 48284.741144414). Metacrine's SIR currently stands at 3.67. In other words for every 100,000 Metacrine shares traded daily on the market, roughly 3670 shares are currently held short.

To gain some more context, you can compare Metacrine's short interest ratio against those of similar companies.

However Metacrine's short interest can also be evaluated against the total number of Metacrine shares, or, against the total number of tradable Metacrine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Metacrine's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Metacrine shares in existence, roughly 10 shares are currently held short) or 0.0132% of the tradable shares (for every 100,000 tradable Metacrine shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Metacrine.

Find out more about how you can short Metacrine stock.

Metacrine share dividends

We're not expecting Metacrine to pay a dividend over the next 12 months.

You may also wish to consider:

Metacrine overview

Metacrine, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site